• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

产毒艰难梭菌聚合酶链反应检测对临床微生物学实验室和住院患者流行病学的影响。

Impact of toxigenic Clostridium difficile polymerase chain reaction testing on the clinical microbiology laboratory and inpatient epidemiology.

机构信息

Wheaton Franciscan Laboratory, Wauwatosa, WI 53226, USA.

出版信息

Diagn Microbiol Infect Dis. 2013 Aug;76(4):534-8. doi: 10.1016/j.diagmicrobio.2013.04.020. Epub 2013 Jun 2.

DOI:10.1016/j.diagmicrobio.2013.04.020
PMID:23731555
Abstract

Conversion from Clostridium difficile toxin A/B EIA to tcdB polymerase chain reaction for diagnosis of C. difficile infection (CDI) resulted in significant decreases in laboratory testing volume and largely unchanged C. difficile toxin detection rates. Decreases in healthcare-associated CDI rates (P ≤ 0.05) reflected a clinical practice benefit of this conversion.

摘要

将艰难梭菌毒素 A/B EIA 转换为 tcdB 聚合酶链反应（PCR）进行艰难梭菌感染（CDI）的诊断，导致实验室检测量显著减少，而艰难梭菌毒素的检测率基本保持不变。与医疗相关的 CDI 发生率的降低（P ≤ 0.05）反映了这种转换的临床实践益处。

相似文献

1
Impact of toxigenic Clostridium difficile polymerase chain reaction testing on the clinical microbiology laboratory and inpatient epidemiology.产毒艰难梭菌聚合酶链反应检测对临床微生物学实验室和住院患者流行病学的影响。
Diagn Microbiol Infect Dis. 2013 Aug;76(4):534-8. doi: 10.1016/j.diagmicrobio.2013.04.020. Epub 2013 Jun 2.
2
[New methodological advances: algorithm proposal for management of Clostridium difficile infection].[新的方法学进展：艰难梭菌感染管理的算法建议]
Rev Esp Quimioter. 2015 Jun;28(3):157-9.
3
Clostridium difficile in adult patients with nosocomial diarrhea in a Costa Rican hospital.哥斯达黎加一家医院成年医院获得性腹泻患者中的艰难梭菌
Am J Trop Med Hyg. 2008 Aug;79(2):164-5.
4
Importance of culture for detection of Clostridium difficile toxin from stool samples to report true incidence and mortality related to C. difficile in hospitals.培养对于从粪便样本中检测艰难梭菌毒素以报告医院中与艰难梭菌相关的真实发病率和死亡率的重要性。
Clin Infect Dis. 2009 Oct 1;49(7):1134-5; author reply 1135. doi: 10.1086/605596.
5
Diagnostic trends in Clostridium difficile detection in Finnish microbiology laboratories.芬兰微生物学实验室中艰难梭菌检测的诊断趋势。
Anaerobe. 2009 Dec;15(6):261-5. doi: 10.1016/j.anaerobe.2009.06.008. Epub 2009 Jul 8.
6
Trends in the use of laboratory tests for the diagnosis of Clostridium difficile infection and association with incidence rates in Quebec, Canada, 2010-2014.2010-2014 年加拿大魁北克省应用实验室检测诊断艰难梭菌感染的趋势及其与发病率的相关性。
Am J Infect Control. 2017 Sep 1;45(9):964-968. doi: 10.1016/j.ajic.2017.04.002. Epub 2017 May 23.
7
Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area.比较 VIDAS CDAB 和 CDA 免疫检测法在 tcdA- tcdB+ 艰难梭菌流行地区检测艰难梭菌的效果。
Anaerobe. 2009 Dec;15(6):266-9. doi: 10.1016/j.anaerobe.2009.09.008. Epub 2009 Sep 20.
8
[The use of two-stage algorithm in the diagnosis of patients with low levels of Clostridium difficile toxins A/B in feces confirmed by using enzyme immunoassay].[应用两阶段算法诊断粪便中艰难梭菌毒素A/B水平较低且经酶免疫测定确诊的患者]
Med Dosw Mikrobiol. 2013;65(4):263-8.
9
Evaluation of three rapid assays for detection of Clostridium difficile toxin A and toxin B in stool specimens.三种快速检测粪便标本中艰难梭菌毒素A和毒素B方法的评估。
Eur J Clin Microbiol Infect Dis. 2007 Feb;26(2):115-9. doi: 10.1007/s10096-006-0251-7.
10
Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile.两步谷氨酸脱氢酶抗原实时聚合酶链反应检测产毒艰难梭菌。
J Hosp Infect. 2010 Jan;74(1):48-54. doi: 10.1016/j.jhin.2009.08.014. Epub 2009 Nov 8.

引用本文的文献

1
Budget Impact Analysis of Adopting a One-Step Nucleic Acid Amplification Testing (NAAT) Alone Diagnostic Pathway for in Japan Compared to a Two-Step Algorithm with Glutamate Dehydrogenase/Toxin Followed by NAAT.与采用谷氨酸脱氢酶/毒素两步法后再进行核酸扩增检测（NAAT）的算法相比，日本采用单一核酸扩增检测（NAAT）诊断途径的预算影响分析。
Diagnostics (Basel). 2023 Apr 18;13(8):1463. doi: 10.3390/diagnostics13081463.
2
Choosing which in-hospital laboratory tests to target for intervention: a scoping review.选择针对干预的院内实验室检测：范围综述。
Clin Chem Lab Med. 2022 Nov 22;61(3):388-401. doi: 10.1515/cclm-2022-0910. Print 2023 Feb 23.
3
Performance Evaluation of the Luminex Aries C. difficile Assay in Comparison to Two Other Molecular Assays within a Multihospital Health Care Center.
在一家多医院医疗中心内，对 Luminex Aries C. difficile 检测与两种其他分子检测方法进行性能评估的比较。
J Clin Microbiol. 2019 Oct 23;57(11). doi: 10.1128/JCM.01092-19. Print 2019 Nov.
4
Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?针锋相对：艰难梭菌感染检测的最佳方法是什么？
J Clin Microbiol. 2017 Mar;55(3):670-680. doi: 10.1128/JCM.02463-16. Epub 2017 Jan 11.
5
Cost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile.艰难梭菌快速分子检测对患者住院时间的成本和影响。
Infect Dis Ther. 2014 Dec;3(2):281-93. doi: 10.1007/s40121-014-0034-x. Epub 2014 Sep 3.